A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
With
Celgene Corporation
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must have what doctors call measurable disease, which will be evaluated before each participant take part of the study.
Must have received both a BTKi and a BCL2i treatment, and their disease must have come back or not responded to treatment, or they must not have been able to tolerate the side-effects of the BTKi and/or BCL2i treatment(s).
Must also have an ECOG performance score of 0 or 1, which means they are able to carry out their normal daily activities without any problems.
You may not be if
Heart problems.
Bleeding disorders.
Active cancer in their brain.
Other reasons include:.
i) Having certain treatments in the past.
ii) Having certain infections that are not under control.
iii) Having certain brain conditions.
Clareo Health | A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies
